Established in 2016, BiVictriX Therapeutics Ltd is a North West based Biotech focused on developing novel, highly-selective, bispecific ADCs to target unmet need in blood cancer.
Through the company’s novel “Dual Targeting Approach”, BiVictriX aims to challenge the conventional ADC therapeutic approach by providing a step change in target selectivity.
Tiffany Thorn BSc. MSc. – Chief Executive Officer
Tiffany Thorn, inventor of the company’s ‘Dual Targeting Approach’, will lead BiVictriX’s operations as CEO.
A co-founder of BiVictriX Therapeutics, Tiffany was previously Marketing and Licensing Manager at ADC Biotechnology Ltd., gaining vital experience of the ADC market and key trends in the sector, before establishing BiVictriX in August 2016.
As a HCPC registered Clinical Immunologist, Tiffany has experience of diagnosing and treating haematological malignancy within a clinical setting and spent several years carrying out this role in the NHS. During this time, Tiffany was awarded the Chief Scientific Officer’s ‘Rising Star Award’ in 2014 for recognition of her work in establishing a regional network to support NHS: Industry collaboration, which was spun out nationally. Tiffany also previously held several technical positions at RedX Pharma Plc, a drug development company focused on the Redox Switch™ technology platform.
Tiffany graduated from Lancaster University with a first class BSc Hons. In Biochemistry with Biomedicine and later gained a MSc Distinction in Clinical Immunology at the University of Manchester.
David Youngman – Non-Executive Director
David has almost 35 years’ experience in stockbroking and corporate finance and will bring corporate finance advise and strong governance practices to BiVictriX in his role as non-executive Director.
David currently holds the position of Corporate Finance Director at Acceleris Capital Ltd., part of Seneca Partners, an Investment Management and Corporate Advisory services group which specialises in the SME sector.
From May 1995 to 2009, David was Managing Director and Head of Corporate Finance at WH Ireland. During that period, WH Ireland grew from one office with a turnover of less than £1 million to 12 UK offices and an Australian subsidiary with turnover in excess of £30 million.
David, over the course of the last nine years of his stockbroking career, was responsible for a portfolio of over 60 companies admitted to AIM.
news - click on the title to read the news story
BiVictriX Therapeutics secures £0.5m seed funding for targeted cancer drug research - January 2017
BiVictriX Therapeutics secures £0.5m seed funding for targeted cancer drug research
BiVictriX Therapeutics (“BVX”) has today announced the completion of a successful fundraise to develop a new class of targeted cancer drugs. The company’s ‘Dual Targeting Approach’ is designed to give superior selectivity towards blood cancers.
Approximately £0.5m has been raised from a syndicate comprising Alderley Park Ventures, Finance Wales and high net worth individuals;
Funds to be used to establish Proof of Principle on the Company’s technology in two lead programmes;
Acceleris Capital Ltd (Manchester UK) provided corporate finance advice to the Company.
Founded in 2016 by serial life sciences entrepreneur Dr Peter Jackson and BVX CEO Tiffany Thorn, the company is focused on developing and licensing novel Antibody Drug Conjugates (“ADCs”), which have been coined as the new ‘Magic Bullet’ therapeutics in the field of oncology. The Company has developed a novel strategy, ‘The Dual Targeting Approach’ that improves ADC selectivity towards cancer cells. The lead and back-up candidate are in the areas of Acute Myeloid Leukaemia (“AML”) and a specific type of agressive Non-Hodgkin Lymphoma, respectively. These areas have been targeted due to a combination of unmet clinical need, market size and the specificity of the targeted antigens.
BVX will focus on developing a platform technology to produce next generation bispecific ADCs with superior tumour selectivity. By exploiting its novel therapeutic strategy, the ‘Dual Targeting Approach’, the Company expects to significantly reduce off-target side effects on healthy tissues. This approach differentiates BVX from mainstream ADC developers by improving selectivity and minimising side effects, which can be significant hurdles in the development of these drugs.
The new investors include Alderley Park Ventures and Finance Wales who both look to back innovative, high-technology companies. The principal use of funds will be to initiate early scientific research to demonstrate Proof of Principle for our approach ahead of establishing technical Proof of Concept and selection of a lead therapeutic candidate.
Commenting on the fundraise, BVX’s CEO Tiffany Thorn said, “We are delighted to close our fundraising with a very strong syndicate of investors who are able to support BVX as we commence operations and look to grow. The Company is now looking forward to demonstrating Proof of Principle for our approach over the next 12 months and have selected a strong panel of service providers to assist in our development now that we have the necessary funds to grow.”
David Youngman, Corporate Finance Director at Acceleris Capital and Non-executive director of BVX, said:
“Acceleris Capital has been delighted to work with BVX to pull together the funding plan and syndicate to allow BVX to commence operations. We are very excited by the potential applications of the ‘Dual Targeting Approach’ in this exciting area of oncology therapeutics.”
Finance Wales Investment Executive Carmine Circelli, said:
“This is an exciting company with strong growth potential. Tiffany and the team have an innovative proposition and we look forward to seeing them commercialize successfully. We’re also pleased to be working with an experienced team of fellow co-investors to support BVX’s expansion in Wales.”
The DWF Corporate team in Manchester acted as legal advisers to the Company in the transaction.
BiVictriX Therapeutics Ltd.
Bio Hub, Alderley Park, Alderley Edge, Cheshire SK10 4TG, UK
+44 (0) 7908 719 566